CRISPR Therapeutics AG (CRSP) EBIT (2015 - 2026)

CRISPR Therapeutics AG has disclosed EBIT across 12 years of filings, most recently posting -$117.3 million for Q2 2026.

• In Q2 2026, EBIT rose 48.86% year-over-year to -$117.3 million; the TTM figure through Jun 2026 stood at -$534.3 million (up 3.28% YoY), while the FY2025 annual figure was -$664.6 million, down 42.44% from the prior year.
• EBIT came in at -$117.3 million for Q2 2026 at CRISPR Therapeutics AG, up from -$130.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $69.6 million in Q4 2023 to a low of -$229.3 million in Q2 2025.
• Average EBIT over 5 years is -$126.4 million, with a median of -$132.2 million recorded in 2023.
• Year-over-year, EBIT soared 152.9% in 2023 and slumped 192.82% in 2024.
• Over 5 years, EBIT stood at -$131.5 million in 2022, then jumped by 152.9% to $69.6 million in 2023, then tumbled by 192.82% to -$64.6 million in 2024, then slumped by 139.62% to -$154.8 million in 2025, then grew by 24.23% to -$117.3 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$117.3 million in Q2 2026, -$130.2 million in Q1 2026, and -$154.8 million in Q4 2025.